OKYO
OKYO Pharma Limited NASDAQ Listed May 17, 2022$1.62
Mkt Cap $62.2M
52w Low $1.32
14.8% of range
52w High $3.35
50d MA $1.63
200d MA $2.10
P/E (TTM)
-13.8x
EV/EBITDA
-6.9x
P/B
—
Debt/Equity
0.0x
ROE
—
P/FCF
-27.7x
RSI (14)
—
ATR (14)
—
Beta
-0.12
50d MA
$1.63
200d MA
$2.10
Avg Volume
211.9K
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
55 Park Lane · London, X0 W1K 1NA · GB
Data updated apr 26, 2026 5:14pm
· Source: massive.com